Clinical trial · Interventional
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Phase I Study of Cabozantinib in Combination With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC), Urothelial Cancer and Advanced Malignant Mesothelioma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Closed by IRB on 3/28/22
Summary
Brief summary (as posted)
This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Mesothelioma | Malignant Mesothelioma | ONTOLOGY_EXACT | 0.98 |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Non-squamous Non-small-cell Lung Cancer | Lung Non-Squamous Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Urothelial Carcinoma | Urothelial Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cabozantinib | Drug | Cabozantinib | ALIAS |
| Pemetrexed | Drug | Pemetrexed | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Cabozantinib + Pemetrexed
- description
- Pemetrexed 500mg/m2 IV day 1 of each 21 day cycle + Cabozantinib 20-60mg by mouth once a day.
- interventionNames
- Drug: Cabozantinib
- Drug: Pemetrexed
Primary outcomes (1)
- measure
- Assess the maximum tolerated dose (MTD) of cabozantinib in combination with pemetrexed
- timeFrame
- 4 weeks or 28 days assessment.
- description
- Dose-limiting toxicity of grade 3 or higher using CTCAE 5
Secondary outcomes (3)
- measure
- Assess objective response rate (RR)
- timeFrame
- To be measured through study completion; an average of 1 year.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Locally advanced NSCLC, urothelial cancer or malignant mesothelioma. * 18 years or older. * At least one prior chemotherapy before entering in this trial. * Not pregnant or breastfeeding. Exclusion Criteria: * Prior treatment with cabozantinib. * Currently receiving cancer treatment (last dose 2 weeks prior to enrollment in study). * History of bleeding disorder/bleeding history within 12 weeks before first study treatment dose.
References
Publications (0)
Data not yet available